Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 296

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 296
---
Amounts in thousands, except share and per share amounts)

| ​                                                                         
 ​                                                                         | ​ 
 ​ |                  ​ 
 For the Year Ended |          ​ | ​ |    ​ |          ​ |
|:--------------------------------------------------------------------------|:--|-------------------:|-----------:|:--|-----:|-----------:|
| ​                                                                         | ​ |       December 31, |            |   |      |            |
| ​                                                                         |   |               2024 |            |   | 2023 |            |
| Operating expenses:                                                       |   |                  ​ |            |   |    ​ |            |
| Research and development                                                  | ​ |                  $ |     23,650 | ​ |    $ |     15,866 |
| General and administrative                                                | ​ |                    |      4,457 | ​ |      |      2,799 |
| Total operating expenses                                                  | ​ |                    |     28,107 | ​ |      |     18,665 |
| Loss from operations                                                      | ​ |                    |    -28,107 | ​ |      |    -18,665 |
| Interest income                                                           | ​ |                    |        747 | ​ |      |      1,318 |
| Other income (expense), net                                               | ​ |                    |     -2,037 | ​ |      |          — |
| Net loss                                                                  | ​ |                  $ |    -29,397 | ​ |    $ |    -17,347 |
| ​                                                                         | ​ |                  ​ |          ​ | ​ |    ​ |          ​ |
| Net loss per share attributable to common stockholders, basic and diluted | ​ |                  $ |      -1.53 | ​ |    $ |      -0.91 |
| Weighted-average common shares outstanding, basic and diluted             | ​ |                    | 19,193,932 | ​ |      | 19,134,096 |

The accompanying notes are an integral part of these financial statements.

F-5

TVARDI THERAPEUTICS, INC. STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT (Amounts in thousands, except share amounts)

| ​                                    
 ​                                    
 ​                                    
 ​                                    | ​ 
 ​ 
 ​ |                      ​ 
 Redeemable Convertible 
        Preferred Stock 
                 Shares | ​ | ​      
 Amount |      ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ |